利拉鲁肽治疗2型糖尿病合并轻中度慢性肾脏病的有效性和安全性分析

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (31 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the clinical efficacy and safety of Liraglutidein in treatment of patients with type 2 diabetes mellitus(T2DM)and mild to moderate chronic kidney disease(CKD).Methods 64 patients with T2DM and mild to moderate CKD in our hospital from June 2014 to June 2015 were randomly divided into 2 groups according to the random number table method,32 cases in each group.All patients received regular treatment,and treatment group received Liraglutidein addition to the regular treatment.The treatment efficacy and safety at following up of 24 weeks between two groups were compared.Results Two patients lost in treatment group and 1 in control group at the end of following up.At 24 weeks,fasting blood glucose(FBG),hemoglobin A1c(HbA1c)and body mass index(BMⅠ)significantly decreased,and fasting insulin(FⅠNS)significantly increased than before therapy in both treatment and control group(all P＜0.05).Compared with control group,treatment group had a greater decline in FBG,HbA1c,BMⅠ,and a greater increase FⅠNS after treatment(all P＜0.05).There were no significant within-group and between-group difference of changes in estimated glomerular filtration rate,serum creatinine,systolic blood pressure,diastolic blood pressure,low-density lipoprotein,triglycerideand total cholesterol(all P＞0.05).There was no significant difference in the incidence of adverse drug reactions between the two groups(all P＞0.05).Conclusion Liraglutide can be considered as an effective and safe agent for glucose lowering and weight loss in patients with T2DM and mild to moderate CKD.However,Liraglutide has no influence on kidney function,blood pressure and blood lipid.

Key words： Liraglutide Type 2 diabetes mellitus Renal disease Adverse reactions

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	CHEN Zuo-ping

Cite this article:

CHEN Zuo-ping. Efficacy and safety analysis of Liraglutide in treatment of patients with type 2 diabetes mellitus and mild to moderate renal disease[J]. 中国当代医药, 2016, 23(30): 131-133.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2016/V23/I30/131

[1]	安玉，刘志红.糖尿病肾病病理改变与预后的关系[J].肾脏病与透析肾移植杂志，2013，22（4）：368-372.
[2]	彭芹，刘理.终末期糖尿病肾病应用腹膜透析治疗的效果分析[J].中国医药导报，2014，11（21）：52-55.
[3]	孔小辉.糖尿病终末期肾病血液透析患者的临床观察[J].中国医药指南，2012，10（29）：480-481.
[4]	Huri HZ，Lim LP，Lim SK.Glycemic control and antidiabetic drugs in type 2 diabetes mellitus patients with renal complications[J].Drug Des Devel Ther，2015，44（9）：4355-4371.
[5]	中国医师协会内分泌代谢科医师分会.2型糖尿病合并慢性肾脏病患者口服降糖药应用原则[J].慢性病学杂志，2013，15（12）：887-892.
[6]	中国医师协会内分泌代谢科医师分会.2型糖尿病合并慢性肾脏病患者口服降糖药用药原则中国专家共识[J].中国糖尿病杂志，2013，21（10）：865-870.
[7]	Manandhar B，Ahn JM.Glucagon-like peptide-1（GLP-1）analogs：recent advances，new possibilities，and therapeutic implications[J].J Med Chem，2015，58（3）：1020-1037.
[8]	中华医学会糖尿病学分会.中国2型糖尿病防治指南[J].中华糖尿病杂志，2014，22（8）：Ⅰ0002-Ⅰ0042.
[9]	吴美芬，武革，蔡晓玲，等.初发2型糖尿病患者GLP-1水平变化对胰高血糖素及早相胰岛素分泌的影响[J].中国临床新医学，2013，6（8）：736-739.
[10]	谭兴容，梁泽容，李生兵，等.GLP-1受体激动剂对锌-α2-糖蛋白的影响及其与胰岛素抵抗关系[J].重庆医科大学学报，2015，40（11）：1395-1400.
[11]	吴美芬，陈晓铭，武革，等.2型糖尿病大鼠胰岛β细胞PDX-1基因表达及GLP-1的干预作用[J].实用医学杂志，2014，43（11）：1699-1701.
[12]	隋春华，吴辉，夏芳珍，等.GLP-1受体激动剂对2型糖尿病大鼠糖脂代谢和小肠L细胞功能的影响[J].上海交通大学学报（医学版），2013，56（12）：1596-1599.
[13]	梁超，周玲.利拉鲁肽联合二甲双胍治疗2型糖尿病的临床疗效[J].中国生化药物杂志，2012，33（5）：656-658.
[14]	张松筠.慢性肾脏病合并糖尿病的治疗[J].临床荟萃，2016，31（6）：631-635.
[15]	李焱.2型糖尿病合并慢性肾脏病患者口服降糖药物的选择[J].中华临床医师杂志（电子版），2015，9（4）：528-530.